SCYNEXIS Inc
scynexis.comWhat Do They Do?
Licenses antifungal drug rights to pharmaceutical partners and develops treatments for severe, difficult-to-treat fungal infections, including drug-resistant infections.
10-K for FY2025, filed Mar 4, 2026SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and…View ↗
Ibrexafungerp is the first representative of this novel class of antifungals and was approved by the U.S. Food and Drug Administration…View ↗
A second generation fungerp SCY-247 is currently being evaluated in clinical trials and additional compounds from our proprietary fungerp…View ↗
We routinely review for potential in-licensing opportunities and are party to a number of licensing and collaboration agreements with…View ↗
How Do They Make Money?
Pharmaceutical partners pay for drug rights and development work. Research payments are earned as the work progresses, while sales royalties and milestones are tied to product sales.
10-K for FY2025, filed Mar 4, 2026On March 30, 2023 and as amended in December 2023 and October 2025, the Company entered into the GSK License Agreement. Pursuant to the…View ↗
The Company evaluated the GSK License Agreement in accordance with ASC 606 as it includes a customer-vendor relationship as defined under…View ↗
The Company considers the future potential regulatory and commercial milestone payments as well as sales-based milestone and royalties to…View ↗
The Company recognizes the revenue associated with the MARIO study over time using an input method. The input method is based on the actual…View ↗
-
10-K for FY2025, filed Mar 4, 2026
FY2025 revenue by product or service ↗
$20.6M
-
10-K for FY2025, filed Mar 4, 2026
$20.6M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product Revenue, Net
|
7.0%
FY2022: 98%
|
Product Revenue, Net, FY2025
$1.4M Sources
|
|
|
License Agreement Revenue
Licensed
10-K for FY2025, filed Mar 4, 2026 |
93%
FY2022: 2.0%
|
License Agreement Revenue, FY2025
$19.2M Sources
|
Licensed |
Who Are Their Customers?
Pharmaceutical partners license drug rights directly from SCYNEXIS; GSK holds the ibrexafungerp rights, while other partners hold rights to other assets or territories.
10-K for FY2025, filed Mar 4, 2026On March 30, 2023 and as amended in December 2023 and October 2025, the Company entered into the GSK License Agreement. Pursuant to the…View ↗
The drug development segment primarily derives revenues from customers by the out licensing of developed drugs which typically include…View ↗
We routinely review for potential in-licensing opportunities and are party to a number of licensing and collaboration agreements with…View ↗
Do Revenues Turn Into Profits?
No. It lost $8.6M in FY2025.
10-K for FY2025, filed Mar 4, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
$7.4MView ↗
- ▲ Now profitable
- vs −$6.9M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 10, 2026
Open tableView ↗
-
Sep 9, 2026
SCYNEXIS appointed a new CFO as its CFO retired
Sanjay Subramanian became CFO, replacing Ivor Macleod.
Sources
8-K, filed Sep 10, 2026
On September 9, 2026, the then-current Chief Financial Officer of SCYNEXIS, Inc. (the “Company” or “SCYNEXIS”), Ivor Macleod, CPA, MBA…View ↗
-
Mar 31, 2026
SCYNEXIS acquired the PXL-770 development program
The acquired program is being developed for a kidney disease.
Sources
8-K, filed Mar 31, 2026
On March 30, 2026, SCYNEXIS, Inc. (the “Company”) and Poxel SA, a French corporation (“Poxel”), entered into an asset purchase agreement…View ↗
Growing. Revenue grew 57% in 4 years, from $13.2M in FY2021 to $20.6M in FY2025, about 12% a year.
Pipeline emphasis
The older report centered on ibrexafungerp for fungal infections in community and hospital settings; the latest report presents another antifungal candidate as a current clinical program while ibrexafungerp is licensed to GSK.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 4, 2026SCYNEXIS, Inc. is pioneering innovative medicines to potentially help millions of patients worldwide in need of new options to overcome and…View ↗
Who Do They Compete With?
Competes with Merck, Astellas, Mycovia Pharmaceuticals, Pfizer, Jannsen, Perrigo, Melinta Therapeutics, Gilead, Dainippon-Sumitomo, Basilea Pharmaceuticals, Matinas BioPharma Holdings, and F2G
10-K for FY2025, filed Mar 4, 2026Azoles. Noxafil® (posaconazole) marketed by Merck and Cresemba® (isavuconazole), approved in the U.S. and other global markets and marketed…View ↗
Loading...
